Canaccord analyst Kyle Rose raised the firm’s price target on Insulet to $355 from $320 and keeps a Buy rating on the shares. The analyst said the target increase is to reflect our updated estimates as well as comparative valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PODD: